Type IV collagen levels are elevated in the serum of patientswith peritoneal dissemination of gastric cancer

Oncology Letters

Volumn 1, Issue 6, 2010, Pages 989-994

  Kinoshita, Jun ^a   Fushida, Sachio ^a   Harada, Shinichi ^b   Makino, Isamu ^a   Nakamura, Keishi ^a   Oyama, Katsunobu ^a   Fujita, Hideto ^a   Ninomiya, Itasu ^a   Fujimura, Takashi ^a   Kayahara, Masato ^a   Ohta, Tetsuo ^a  

^a Graduate School of Medical Science   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Peritoneal dissemination; Type iv collagen

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLLAGEN TYPE 4; PROCOLLAGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LAPAROSCOPY; LAPAROTOMY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERITONEUM; PERITONEUM CANCER; PREDICTION; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SERUM; STOMACH CANCER;

EID: 77957953204     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.181     Document Type: Article

References (42)

1. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999.
2. Yamazaki H, Oshima A, Murakami R, Endoh S and UbukataT: A long-term follow-up study of patients with gastric cancer detected by mass screening. Cancer 63: 613-617, 1989.
3. Ikeguchi M, Yamamoto O and Kaibara N: Management protocol for scirrhous gastric cancer. In Vivo 18: 577-580, 2004.
4. Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY and Shen KH: Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology 49: 874-877, 2002.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, VoznyiE, Risse MLand Ajani JA; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
6. Glehen O, Mohamed F and Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5: 219-228, 2004.
7. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, OtaniK, Kamei T, Soma D, Miyato H, Yamashita H and NagawaH: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21: 67-70, 2010.
8. Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, NinomiyaI, Fujimura T, Nishimura G, Kayahara M and Ohta T: Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep 19: 1305-1310, 2008.
9. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, TakiyamaW, Sato Y, Todo S, Terashima M, Gotoh M, SakamotoJ and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006.
10. Burke EC, Karpeh MS, Conlon KC and Brennan MF: Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 225: 262-267, 1997.
11. Gretschel S, Siegel R, Estévez-Schwarz L, Hünerbein M, Schneider U and Schlag PM: Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg 93: 1530-1535, 2006.
12. Sendler A, Dittler HJ, Feussner H, Nekarda H, BollschweilerE, Fink U, Helmberger H, Höfler H and Siewert JR: Preoperative staging of gastric cancer as precondition for multimodal treatment. World J Surg 19: 501-508, 1995.
13. Davies J, Chalmers AG, Sue-Ling HM, May J, Miller GV, MartinIG and Johnston D: Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut 41: 314-319, 1997.
14. Düx M, Richter GM, Hansmann J, Kuntz C and Kauffmann GW: Helical hydro-CT for diagnosis and staging of gastric carcinoma. J Comput Assist Tomogr 23: 913-922, 1999.
15. Yang QM, Bando E, Kawamura T, Tsukiyama G, Nemoto M, Yonemura Y and Furukawa H: The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho 33: 1817-1821, 2006.
16. Nakata B, Hirakawa-YS Chung K, Kato Y, Yamashita Y, MaedaK and Onoda N: Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 83: 2488-2492, 1998.
17. Yashiro M, Chung YS, Nishimura S, Inoue T and Sowa M: Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as 'soil' for peritoneal dissemination. Cancer 77: 1668-1675, 1996.
18. Gabrielli GB and Corrocher R: Hepatic fibrosis and its serum markers. Dig Dis 9: 303-316, 1991.
19. Yamada S, Suou T, Kawasaki H and Yoshikawa N: Clinical significance of serum 7S collagen in various liver diseases. Clin Biochem 25: 467-470, 1992.
20. Jeffers LJ, Coelho-Little ME, Cheinquer H, Vargas C, CivantosF and Alvarez L: Procollagen-III peptide and chronic viral C hepatitis. Am J Gastroenterol 90: 1437-1440, 1995.
21. th edition. Kanehara Shuppan, Tokyo, 1993.
22. Kasuga I, Yonemaru M, Kiyokawa H, Ichinose Y and Toyama K: Clinical evaluation of serum type IV collagen 7S in idiopathic pulmonary fibrosis. Respirology 1: 277-281, 1996.
23. Sato Y, Kataoka K, Matsumori A, Sasayama S, Yamada T and Ito H: Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 78: 505-508, 1997.
24. Guseva NG, Anikina NV, Myllylä R, Risteli L, Risteli J and Chochlova JV: Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis. Ann Rheum Dis 50: 481-486, 1991.
25. Xu X, Wu Z, Zhou Q, Zhang Y and Wu D: The role of determining the levels of serum collagen type IV in diagnosing early diabetic nephropathy. Ren Fail 24: 747-753, 2002.
26. Katayama M, Hino F, Kamihagi K, Sekiguchi K, Titani K and Kato I: Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymometric assay with domain-specific monoclonal antibodies. Clin Chem 37: 466-471, 1991.
27. Basso D, Belluco C, Mazza S, Greco E, Della Rocca F, PaulettoP, Nitti D, Lise M and Plebani M: Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen: clinical implications for prognosis. Clin Chim Acta 312: 135-142, 2001.
28. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, WangB, Hortobagyi GN, Buzdar AU and Pusztai L: CollagenIV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 99: 68-71, 2008.
29. Akazawa S, Fujiki T, Kanda Y, Kumai R and Yoshida S: Diagnostic values of serum type III procollagen N-terminal peptide in type IV gastric cancer. Gan To Kagaku Ryoho 12: 861-866, 1985.
30. Korenaga D, Orita H, Maekawa S, Itasaka H, Ikeda T and Sugimachi K: Peritoneal collagen type IV concentration in adenocarcinoma of the gastrointestinal tract and its relationship to histological differentiation, metastasis, and survival. Surg Today 28: 780-786, 1998.
31. Baker SG: The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 95: 511-515, 2003.
32. Martinez-Hernandez A and Amenta PS: The basement membrane in pathology. Lab Invest 48: 656-677, 1983.
33. Liotta LA: Tumor invasion and metastases - role of the extracellular matrix. Cancer Res 46: 1-7, 1986.
34. Meyer T and Hart IR: Mechanisms of tumor metastasis. Eur J Cancer 34: 214-221, 1998.
35. Conway JG, Trexler SJ, Wakefield JA, Marron BE, Emerson DL and Bickett DM: Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis 14: 115-124, 1996.
36. Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273-282, 1996.
37. Mori M, Mimori K, Shiraishi T, Fujie T, Baba K, KusumotoH, Haraguchi M, Ueo H and Akiyoshi T: Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 74: 316-321, 1997.
38. De Mingo M, Morán A, Sánchez-Pernaute A, Iniesta P, Díez-Valladares L, Pérez-Aguirre E, de Juan C, García-Aranda C, Díaz-López A, García-Botella A, Martín-Antona E, Benito M, Torres A and Balibrea JL: Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 54: 315-319, 2007.
39. Duffy MJ, Maguire TM, Hill A, McDermott E and O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252-257, 2000.
40. Kenny HA, Kaur S, Coussens LM and Lengyel E: The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 118: 1367-1379, 2008.
41. Sun XM, Dong WG, Yu BP, Luo HS and Yu JP: Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol 9: 2592-2595, 2003.
42. Minamoto T, Ooi A, Okada Y, Mai M, Nagai Y and NakanishiI: Desmoplastic reaction of gastric carcinoma: a light- and electron-microscopic immunohistochemical analysis using collagen type-specific antibodies. Hum Pathol 19: 815-821, 1998.